ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Fundamental Analysis & Valuation

NASDAQ:ADAP • US00653A1079

Current stock price

0.0549 USD
-0.01 (-15.15%)
At close:
0.0579 USD
+0 (+5.46%)
After Hours:

This ADAP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ADAP Profitability Analysis

1.1 Basic Checks

  • ADAP had negative earnings in the past year.
  • ADAP had a negative operating cash flow in the past year.
  • In the past 5 years ADAP always reported negative net income.
  • In the past 5 years ADAP reported 4 times negative operating cash flow.
ADAP Yearly Net Income VS EBIT VS OCF VS FCFADAP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • ADAP has a worse Return On Assets (-129.95%) than 82.46% of its industry peers.
Industry RankSector Rank
ROA -129.95%
ROE N/A
ROIC N/A
ROA(3y)-39.8%
ROA(5y)-36.38%
ROE(3y)-362.62%
ROE(5y)-240.54%
ROIC(3y)N/A
ROIC(5y)N/A
ADAP Yearly ROA, ROE, ROICADAP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • With an excellent Gross Margin value of 273.43%, ADAP belongs to the best of the industry, outperforming 99.63% of the companies in the same industry.
  • ADAP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 273.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADAP Yearly Profit, Operating, Gross MarginsADAP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. ADAP Health Analysis

2.1 Basic Checks

  • ADAP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ADAP has been increased compared to 1 year ago.
  • Compared to 5 years ago, ADAP has more shares outstanding
  • Compared to 1 year ago, ADAP has a worse debt to assets ratio.
ADAP Yearly Shares OutstandingADAP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ADAP Yearly Total Debt VS Total AssetsADAP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • ADAP has an Altman-Z score of -15.45. This is a bad value and indicates that ADAP is not financially healthy and even has some risk of bankruptcy.
  • ADAP's Altman-Z score of -15.45 is on the low side compared to the rest of the industry. ADAP is outperformed by 80.41% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.45
ROIC/WACCN/A
WACC8.77%
ADAP Yearly LT Debt VS Equity VS FCFADAP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 1.52 indicates that ADAP should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.52, ADAP is not doing good in the industry: 81.34% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.29 indicates that ADAP should not have too much problems paying its short term obligations.
  • ADAP's Quick ratio of 1.29 is on the low side compared to the rest of the industry. ADAP is outperformed by 83.21% of its industry peers.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.29
ADAP Yearly Current Assets VS Current LiabilitesADAP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ADAP Growth Analysis

3.1 Past

  • The earnings per share for ADAP have decreased strongly by -21.05% in the last year.
  • The Revenue for ADAP has decreased by -53.99% in the past year. This is quite bad
  • ADAP shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 175.59% yearly.
EPS 1Y (TTM)-21.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
Revenue 1Y (TTM)-53.99%
Revenue growth 3Y207.05%
Revenue growth 5Y175.59%
Sales Q2Q%-89.33%

3.2 Future

  • Based on estimates for the next years, ADAP will show a very strong growth in Earnings Per Share. The EPS will grow by 38.30% on average per year.
  • ADAP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.60% yearly.
EPS Next Y-152.32%
EPS Next 2Y-63.84%
EPS Next 3Y-34.18%
EPS Next 5Y38.3%
Revenue Next Year-85.59%
Revenue Next 2Y-52.1%
Revenue Next 3Y-13.59%
Revenue Next 5Y12.6%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADAP Yearly Revenue VS EstimatesADAP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ADAP Yearly EPS VS EstimatesADAP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. ADAP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ADAP. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADAP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADAP Price Earnings VS Forward Price EarningsADAP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADAP Per share dataADAP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • A cheap valuation may be justified as ADAP's earnings are expected to decrease with -34.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.84%
EPS Next 3Y-34.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ADAP Dividend Analysis

5.1 Amount

  • ADAP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ADAP Fundamentals: All Metrics, Ratios and Statistics

ADAPTIMMUNE THERAPEUTICS-ADR

NASDAQ:ADAP (10/27/2025, 10:02:27 PM)

After market: 0.0579 +0 (+5.46%)

0.0549

-0.01 (-15.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13
Earnings (Next)11-11
Inst Owners31.35%
Inst Owner Change-92.78%
Ins Owners0.29%
Ins Owner Change0%
Market Cap14.55M
Revenue(TTM)65.08M
Net Income(TTM)-169.76M
Analysts40
Price Target0.28 (410.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.86%
Min EPS beat(2)-24.87%
Max EPS beat(2)80.59%
EPS beat(4)2
Avg EPS beat(4)18.25%
Min EPS beat(4)-75.07%
Max EPS beat(4)92.37%
EPS beat(8)3
Avg EPS beat(8)30.42%
EPS beat(12)6
Avg EPS beat(12)25.8%
EPS beat(16)6
Avg EPS beat(16)-0.97%
Revenue beat(2)2
Avg Revenue beat(2)24.66%
Min Revenue beat(2)15.67%
Max Revenue beat(2)33.64%
Revenue beat(4)3
Avg Revenue beat(4)66.46%
Min Revenue beat(4)-42.36%
Max Revenue beat(4)258.91%
Revenue beat(8)4
Avg Revenue beat(8)34.35%
Revenue beat(12)7
Avg Revenue beat(12)109.28%
Revenue beat(16)8
Avg Revenue beat(16)74.59%
PT rev (1m)0%
PT rev (3m)-75.81%
EPS NQ rev (1m)-41.18%
EPS NQ rev (3m)-44.58%
EPS NY rev (1m)-11.9%
EPS NY rev (3m)-2.29%
Revenue NQ rev (1m)-52.76%
Revenue NQ rev (3m)-75.83%
Revenue NY rev (1m)-21.69%
Revenue NY rev (3m)-44.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.22
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.25
BVpS-0.27
TBVpS-0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -129.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 273.43%
FCFM N/A
ROA(3y)-39.8%
ROA(5y)-36.38%
ROE(3y)-362.62%
ROE(5y)-240.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.15%
Cap/Sales 4.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.52
Quick Ratio 1.29
Altman-Z -15.45
F-Score1
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)187.66%
Cap/Depr(5y)146.98%
Cap/Sales(3y)39.72%
Cap/Sales(5y)67.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
EPS Next Y-152.32%
EPS Next 2Y-63.84%
EPS Next 3Y-34.18%
EPS Next 5Y38.3%
Revenue 1Y (TTM)-53.99%
Revenue growth 3Y207.05%
Revenue growth 5Y175.59%
Sales Q2Q%-89.33%
Revenue Next Year-85.59%
Revenue Next 2Y-52.1%
Revenue Next 3Y-13.59%
Revenue Next 5Y12.6%
EBIT growth 1Y-99.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-99.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-33.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.43%
OCF growth 3YN/A
OCF growth 5YN/A

ADAPTIMMUNE THERAPEUTICS-ADR / ADAP Fundamental Analysis FAQ

What is the fundamental rating for ADAP stock?

ChartMill assigns a fundamental rating of 2 / 10 to ADAP.


What is the valuation status of ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) stock?

ChartMill assigns a valuation rating of 0 / 10 to ADAPTIMMUNE THERAPEUTICS-ADR (ADAP). This can be considered as Overvalued.


How profitable is ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) stock?

ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) has a profitability rating of 1 / 10.